Light-Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A light-activated polycaprolactone dimethacrylate (PCM) and hydroxyethyl methacrylate (HEMA) based gel network was developed to sustain the release of stable, active bevacizumab (an anti-VEGF antibody used to treat choroidal neovascularization) and used to assess sustained ex vivo delivery in rabbit eyes and in vivo delivery in rat eyes following in situ gel formation in the suprachoroidal space. PCM was synthesized from polycaprolactone diol (PCD) and evaluated using NMR spectroscopy. PCM was used to cross-link HEMA in the presence of 365 nm UV light and 2,2-dimethoxy-2-phenylacetophenone (DMPA) as a photoinitiator. Bevacizumab was entrapped in the gel using three different cross-linking durations of 3, 7, and 10 min. In vitro release of bevacizumab in PBS pH 7.4 at 37 °C during a 4 month study was quantified using a VEGF-binding based ELISA. The stability of released bevacizumab was monitored by size exclusion chromatography (SEC) and circular dichroism. Alexa Fluor 488 dye conjugated bevacizumab mixed with polymers was injected suprachoroidally in rabbit eyes to study the effect of different cross-linking durations on the spread of the dye conjugated bevacizumab. In vivo delivery was assessed in Sprague-Dawley (SD) rats by injecting Alexa Fluor 488 dye conjugated bevacizumab mixed with polymers followed by cross-linking for 10 min. Spread in the rabbit eyes and in vivo delivery in rat eyes was monitored noninvasively using a fundus camera and Fluorotron Master. The formation of PCM was confirmed by the disappearance of hydroxyl peak in NMR spectra. A cross-linking duration of 10 min resulted in a burst release of 21% of bevacizumab. Other cross-linking durations had ≥62% burst release. Bevacizumab release from 10 min cross-linked gel was sustained for ∼4 months. Release samples contained ≥96.1% of bevacizumab in the monomeric form as observed in SEC chromatograms. Circular dichroism confirmed that secondary β-sheet structure of bevacizumab was maintained after release from the gel. As the cross-linking duration was increased to 10 min, the gel/antibody was better confined at the injection site in excised rabbit eye suprachoroidal space. Delivery of Alexa Fluor 488 dye conjugated bevacizumab was sustained for at least 60 days in the suprachoroidal space of SD rats. PCM and HEMA gel sustained bevacizumab release for 4 months and maintained the stability and VEGF-binding activity of bevacizumab. Therefore, light-activated PCM and HEMA gel is suitable for in situ gel formation and sustained protein delivery in the suprachoroidal space.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats
Li, Y.-P., Pei, Y.-Y., Zhang, X.-Y., Gu, Z.-H., Zhou, Z.-H., Yuan, W.-F., Zhou, J.-J., Zhu, J.-H., & Gao, X.-J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00218-8 · Cited by 540
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
Lam, C. X. F., Savalani, M. M., Teoh, S.-H., & Hutmacher, D. W. (2008) · Biomedical Materials · doi:10.1088/1748-6041/3/3/034108 · Cited by 444
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330
Bhutto, I. A., McLeod, D. S., Hasegawa, T., Kim, S. Y., Merges, C., Tong, P., & Lutty, G. A. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2005.05.007 · Cited by 275
Liu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6431 · Cited by 199
Olsen, T. W., Feng, X., Wabner, K., Csaky, K., Pambuccian, S., & Cameron, J. D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6291 · Cited by 106
Cited by
Nanotechnology-based strategies for treatment of ocular disease
Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.001 · Cited by 375
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Drug delivery via the suprachoroidal space for the treatment of retinal diseases
Naftali Ben Haim, L., & Moisseiev, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070967 · Cited by 68
“into the SCS of rabbits in vivo, that was detectable for about 6 months; light-activated polycaprolactone dimethacrylate (PCM) and hydroxyethyl methacrylate (HEMA)-based gel network, entrapping bevacizumab injected into the SCS of rabbit eyes ex vivo and rat eyes in vivo, which released bevacizumab for 4 months and ma…”
BackgroundMedical and Surgical Applications for the Suprachoroidal Space
Emami-Naeini, P., & Yiu, G. (2019) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000251 · Cited by 41
Naik, S., Shreya, A. B., Raychaudhuri, R., Pandey, A., Lewis, S. A., Hazarika, M., Bhandary, S. V., Rao, B. S. S., & Mutalik, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118712 · Cited by 33
Metadata
- Authors
- Tyagi, P., Barros, M., Stansbury, J. W., & Kompella, U. B.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-07-08
- Volume
- 10
- Issue
- 8
- Pages
- 2858-2867
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2033254969
- Cited by
- 103
- References
- 7
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Light-Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab. https://app.cochat.ai/papers/10.1021/mp300716t
- The paper
- Tyagi, P., Barros, M., Stansbury, J. W., & Kompella, U. B. (2013). Light-Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab. Molecular Pharmaceutics. https://doi.org/10.1021/mp300716t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.